{"organizations": [], "uuid": "c0afef92db8cddf012b296b5653affc82079817b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-provides-update-on-proposed/brief-pfizer-provides-update-on-proposed-trastuzumab-biosimilar-idUSASC09WRN", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T14:46:00.000+03:00", "replies_count": 0, "uuid": "c0afef92db8cddf012b296b5653affc82079817b"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-provides-update-on-proposed/brief-pfizer-provides-update-on-proposed-trastuzumab-biosimilar-idUSASC09WRN", "ord_in_thread": 0, "title": "BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "united states fda", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "biosimilar reuters", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 11:47 AM / Updated 13 minutes ago BRIEF-Pfizer Provides Update On Proposed Trastuzumab Biosimilar Reuters Staff April 23 (Reuters) - Pfizer Inc: * PFIZER PROVIDES UPDATE ON PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER INC - IN CRL, FDA HIGHLIGHTED NEED FOR ADDITIONAL TECHNICAL INFORMATION * PFIZER INC - RECEIVED CRL FROM UNITED STATES FDA IN RESPONSE TO BIOLOGICS LICENSE APPLICATION FOR COMPANY‘S PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER - ADDITIONAL REQUESTED INFORMATION BY FDA DOES NOT RELATE TO SAFETY OR CLINICAL DATA SUBMITTED IN BLA FOR CO‘S PROPOSED TRASTUZUMAB BIOSIMILAR * PFIZER - “WORKING CLOSELY” WITH FDA TO ADDRESS CONTENTS OF LETTER ON PROPOSED TRASTUZUMAB BIOSIMILAR Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-23T14:46:00.000+03:00", "crawled": "2018-04-23T15:05:27.008+03:00", "highlightTitle": ""}